Any feedback?
Information on EC 3.5.1.1 - asparaginase and Organism(s) Homo sapiens
for references in articles please use BRENDA:EC3.5.1.1Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.5.1.1 asparaginaseSpecify your search results
Word Map
- 3.5.1.1
- leukemia
- lymphoblastic
- children
-
remission
- erwinia
- hypersensitivity
- methotrexate
- lymphoma
- vincristine
-
pegylated
-
relapse
- pancreatitis
- thrombosis
- prednisone
-
high-dose
- venous
-
oncology
-
event-free
-
schedule
- cytarabine
-
consolidation
-
intensification
-
antileukemic
-
intrathecal
- antithrombin
-
l-aspartic
- chrysanthemi
- anthracyclines
- medicine
-
reinduction
- cyclophosphamide
-
pegaspargase
- thromboembolism
- allergy
- acrylamide
-
arabinoside
- mercaptopurine
- daunorubicin
- osteonecrosis
- analysis
-
philadelphia
-
extranodal
-
fried
-
b-precursor
- succinogenes
-
standard-risk
- synthesis
-
coli-derived
- food industry
- diagnostics
- biotechnology
-
dana-farber
- pharmacology
- teniposide
- carotovora
-
multiagent
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota, Archaea
The expected taxonomic range for this enzyme is: Bacteria, Eukaryota, Archaea
Synonyms
asparaginase, l-asnase, asrgl1, asparaginase ii, l-asparaginase ii, erwinase, ecaii, l-asparaginase i, ecaiii, diasp, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
alpha-asparaginase
-
-
-
-
asparaginase II
-
-
-
-
colaspase
-
-
-
-
crasnitin
-
-
-
-
DiAsp
-
-
-
-
elspar
-
-
-
-
L-ASNase
-
-
-
-
L-asparaginase
L-asparagine amidohydrolase
-
-
-
-
leunase
-
-
-
-
L-asparaginase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
carboxylic acid amide hydrolysis
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
KEGG
-
-, -, -
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
L-asparagine amidohydrolase
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9015-68-3
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
additional information
?
-
-
L-asparaginase is cytotoxic, resistance to L-asparaginase in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic cells is due to increased cellular expression of asparagine synthase, overview
-
-
?
additional information
?
-
to become enzymatically active, ASNase3 must undergo autocleavage between residues Gly167 and Thr168
-
-
?
additional information
?
-
-
to become enzymatically active, ASNase3 must undergo autocleavage between residues Gly167 and Thr168
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
additional information
?
-
-
L-asparaginase is cytotoxic, resistance to L-asparaginase in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic cells is due to increased cellular expression of asparagine synthase, overview
-
-
?
additional information
?
-
to become enzymatically active, ASNase3 must undergo autocleavage between residues Gly167 and Thr168
-
-
?
additional information
?
-
-
to become enzymatically active, ASNase3 must undergo autocleavage between residues Gly167 and Thr168
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
glycine
the enzyme is activated by incubating for 4 days in a 2.0 M glycine (pH 9.0) solution at room temperature
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma.
Adenocarcinoma
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Adenocarcinoma
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Adenocarcinoma
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Adenocarcinoma
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Adenocarcinoma of Lung
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Adenocarcinoma of Lung
Sleeping Beauty Transposon-Mediated Asparaginase Gene Delivery by a Nanoparticle Platform.
Anaphylaxis
Anaphylactic reaction to polyethylene glycol-conjugated asparaginase: premedication and desensitization may not be sufficient.
Anaphylaxis
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Anaphylaxis
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Anaphylaxis
Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures.
Anaphylaxis
Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Anaphylaxis
Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli.
Anaphylaxis
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Anaphylaxis
Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.
Anaphylaxis
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
Anaphylaxis
[A technic for "desensitization" in case of asparaginase anaphylaxis during acute leukemia]
Antiphospholipid Syndrome
Thromboembolic complications related to indwelling central venous catheters in children.
Antithrombin III Deficiency
Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia.
Antithrombin III Deficiency
Antithrombin III deficiency during asparaginase therapy.
Aspartylglucosaminuria
Large-scale purification and preliminary x-ray diffraction studies of human aspartylglucosaminidase.
Asthenozoospermia
An in silico analysis of human sperm genes associated with asthenozoospermia and its implication in male infertility.
Ataxia Telangiectasia
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Blast Crisis
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Blast Crisis
Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.
Bone Diseases, Developmental
Exceptional thermal stability of therapeutical enzymes entrapped in alumina sol-gel matrices.
Bone Diseases, Metabolic
Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia.
Brain Diseases
Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase.
Brain Diseases
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Brain Diseases
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Brain Diseases
On the origin of EEG-slowing and encephalopathy during induction treatment of acute lymphoblastic leukemia.
Brain Diseases, Metabolic
Acute metabolic encephalopathy in two patients treated with asparaginase and ondasetron.
Breast Neoplasms
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Breast Neoplasms
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Burkitt Lymphoma
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Burkitt Lymphoma
[Physico-chemical properties of deamidase AG from Pseudomonas fluorescens AG possessing antitumor activity]
Carcinogenesis
ASRGL1 Correlates With Immune Cell Infiltration in Hepatocellular Carcinoma and Can Serve as a Prognostic Biomarker.
Carcinogenesis
Genome-Wide Profiling of Cervical RNA-Binding Proteins Identifies Human Papillomavirus Regulation of RNASEH2A Expression by Viral E7 and E2F1.
Carcinogenesis
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Carcinoma
Asparaginase induces selective dose- and time-dependent cytotoxicity, apoptosis, and reduction of NF?B expression in oral cancer cells.
Carcinoma
Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase.
Carcinoma, Ductal
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Carcinoma, Hepatocellular
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.
Carcinoma, Hepatocellular
ASRGL1 Correlates With Immune Cell Infiltration in Hepatocellular Carcinoma and Can Serve as a Prognostic Biomarker.
Carcinoma, Renal Cell
Human renal carcinoma: asparagine independence with asparaginase susceptibility in culture.
Chemical and Drug Induced Liver Injury
Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.
Chemical and Drug Induced Liver Injury
Natural Killer-Like T-Cell Lymphoma: A Rare Cause of Acute Liver Failure.
Choledocholithiasis
Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Cholelithiasis
Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Colonic Neoplasms
Glutaraldehyde-Mediated Synthesis of Asparaginase-Bound Maghemite Nanocomposites: Cytotoxicity against Human Colon Adenocarcinoma Cells.
Colorectal Neoplasms
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.
Colorectal Neoplasms
Free Asparagine or Die: Cancer Cells Require Proteasomal Protein Breakdown to Survive Asparagine Depletion.
Consciousness Disorders
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Dehydration
Industrially Applicable Strategies for Mitigating Acrylamide, Furan and 5-Hydroxymethylfurfural in Food.
Diabetes Mellitus, Type 2
Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.
Disseminated Intravascular Coagulation
Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan.
Drug-Related Side Effects and Adverse Reactions
Asparaginase in acute lymphoblastic leukemia.
Duodenal Ulcer
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Dyslipidemias
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Encephalomyelitis
[ASPARAGINASE IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. 3. ASPARAGINASE IN THE LYMPH NODES AND SPLEEN IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN GUINEA PIGS.]
Encephalomyelitis
[Asparaginase in experimental allergic encephalomyelitis. IV. The relation of asparaginase of lymph nodes to asparaginase of the central nervous system in the process of development of experimental allergic encephalomyelitis in guinea pigs. The relationship between the histologic finding, the clinical picture and the asparaginase in the central nervous system]
Encephalomyelitis, Autoimmune, Experimental
ASPARAGINASE IN THE BRAIN OF GUINEA PIG IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS.
Encephalomyelitis, Autoimmune, Experimental
[ASPARAGINASE ACTIVITY IN THE NERVOUS SYSTEM IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. II.]
Encephalomyelitis, Autoimmune, Experimental
[ASPARAGINASE IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. 3. ASPARAGINASE IN THE LYMPH NODES AND SPLEEN IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN GUINEA PIGS.]
Encephalomyelitis, Autoimmune, Experimental
[Asparaginase in experimental allergic encephalomyelitis. IV. The relation of asparaginase of lymph nodes to asparaginase of the central nervous system in the process of development of experimental allergic encephalomyelitis in guinea pigs. The relationship between the histologic finding, the clinical picture and the asparaginase in the central nervous system]
Endometrial Neoplasms
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
Endometrial Neoplasms
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Endometrial Neoplasms
Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
Endometrial Neoplasms
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Fatty Liver
Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
Fatty Liver
L-Asparaginase-Induced Hepatotoxicity Treated Successfully With L-Carnitine and Vitamin B Infusion.
Gastritis
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Glioblastoma
Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase
Glioma
Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma.
Hematologic Neoplasms
Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia.
Hematologic Neoplasms
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.
Hematologic Neoplasms
Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy().
Hematologic Neoplasms
[Fatal central nervous system hemorrhage during acute lymphoblastic leukemia induction].
Hepatic Veno-Occlusive Disease
Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Hepatic Veno-Occlusive Disease
[Hemostasis tests as markers of hepatic and endothelial toxicity in chemotherapy]
Hypercholesterolemia
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Hypercholesterolemia
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Hypercholesterolemia
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Hyperglycemia
Comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Hyperglycemia
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Hyperglycemia
Glucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Hyperglycemia
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes.
Hyperglycemia
Hyperglycemic Hyperosmolar State During Induction Chemotherapy for Acute Lymphoblastic Leukemia.
Hyperglycemia
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Hyperglycemia
Incidence of Hyperglycemia during Induction of Remission Phase of Pediatric Acute Lymphoblastic Leukemia.
Hyperglycemia
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Hyperglycemia
Reply to comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Hyperglycemia
Safety and Efficacy of Metformin for Therapy-induced Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Hyperglycemia
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Hyperlipidemias
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
Hyperlipidemias
Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report.
Hyperlipidemias
L-Asparaginase and Steroids-associated Hypertriglyceridemia Successfully Treated With Plasmapheresis in a Child With Acute Lymphoblastic Leukemia.
Hyperlipidemias
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Hyperlipidemias
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
Hyperlipidemias
[Transient hyperlipidemia secondary to treatment with asparaginase and prednisone]
Hypersensitivity
A 12-steps desensitization protocol for pediatric patients with hypersensitivity to pegylated asparaginase.
Hypersensitivity
A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
Hypersensitivity
A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.
Hypersensitivity
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Hypersensitivity
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Hypersensitivity
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
Hypersensitivity
A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage.
Hypersensitivity
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Hypersensitivity
Adequate asparaginase is important to prevent central nervous system and testicular relapse of pediatric Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
Hypersensitivity
Allergic reactions to asparaginase: Retrospective cohort study in pediatric patients with acute lymphoid leukemia.
Hypersensitivity
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Hypersensitivity
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Hypersensitivity
Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
Hypersensitivity
Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
Hypersensitivity
Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Hypersensitivity
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.
Hypersensitivity
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Hypersensitivity
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
Hypersensitivity
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Hypersensitivity
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Hypersensitivity
Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Hypersensitivity
Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Hypersensitivity
Asparaginase immune complexes induce Fc-?RIII-dependent hypersensitivity in naive mice.
Hypersensitivity
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hypersensitivity
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Hypersensitivity
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Hypersensitivity
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hypersensitivity
Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Hypersensitivity
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
Hypersensitivity
Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Hypersensitivity
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
Hypersensitivity
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Hypersensitivity
Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Hypersensitivity
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
Hypersensitivity
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
Hypersensitivity
CORRIGENDUM: Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity.
Hypersensitivity
Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Hypersensitivity
Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
Hypersensitivity
Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Hypersensitivity
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Hypersensitivity
Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
Hypersensitivity
Effect of premedications in a murine model of asparaginase hypersensitivity.
Hypersensitivity
Effects of polyethylene glycol attachment on physicochemical and biological stability of E. coli L-asparaginase.
Hypersensitivity
Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
Hypersensitivity
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Hypersensitivity
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
Hypersensitivity
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Hypersensitivity
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Hypersensitivity
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Hypersensitivity
Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
Hypersensitivity
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
Hypersensitivity
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Hypersensitivity
Genetic inhibition of NFATC2 attenuates asparaginase hypersensitivity in mice.
Hypersensitivity
Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
Hypersensitivity
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity.
Hypersensitivity
Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.
Hypersensitivity
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
Hypersensitivity
HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.
Hypersensitivity
HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.
Hypersensitivity
How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Hypersensitivity
Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Hypersensitivity
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
Hypersensitivity
Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS.
Hypersensitivity
Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors Fc?RI and Fc?RIII.
Hypersensitivity
Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Hypersensitivity
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Hypersensitivity
Is Erwinase Necessary for all Children With ALL and Allergic Reactions to E. coli Asparaginase?
Hypersensitivity
L-asparaginase in the treatment of patients with acute lymphoblastic leukemia.
Hypersensitivity
l-Asparaginase Production by Moderate Halophilic Bacteria Isolated from Maharloo Salt Lake.
Hypersensitivity
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Hypersensitivity
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Hypersensitivity
Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
Hypersensitivity
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Hypersensitivity
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Hypersensitivity
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Hypersensitivity
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Hypersensitivity
Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Hypersensitivity
PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review.
Hypersensitivity
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Hypersensitivity
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Hypersensitivity
PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.
Hypersensitivity
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
Hypersensitivity
Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Hypersensitivity
Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Hypersensitivity
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL.
Hypersensitivity
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Hypersensitivity
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458).
Hypersensitivity
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Hypersensitivity
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Hypersensitivity
Review of pharmacogenetics studies of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene.
Hypersensitivity
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
Hypersensitivity
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Hypersensitivity
Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
Hypersensitivity
Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Hypersensitivity
Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.
Hypersensitivity
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
Hypersensitivity
The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.
Hypersensitivity
The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia.
Hypersensitivity
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Hypersensitivity
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Hypersensitivity
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Hypersensitivity
Tolerability and Efficacy of a 1-Bag Pegaspargase Densensitization Protocol in Pediatric Oncology Patients.
Hypersensitivity
Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
Hypersensitivity
Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
Hypersensitivity
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Hypersensitivity
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Hypersensitivity
Two tagging single-nucleotide polymorphisms to capture HLA-DRB1*07:01-DQA1*02:01-DQB1*02:02 haplotype associated with asparaginase hypersensitivity.
Hypersensitivity
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Hypersensitivity
Use of a protocol to minimize hypersensitivity reactions with asparaginase administration.
Hypersensitivity
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Hypersensitivity
[Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
Hypersensitivity
[New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase]
Hypersensitivity, Immediate
Effect of premedications in a murine model of asparaginase hypersensitivity.
Hypertension
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Hypertension
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Hypertriglyceridemia
A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis.
Hypertriglyceridemia
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Hypertriglyceridemia
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Hypertriglyceridemia
Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment.
Hypertriglyceridemia
Cerebral sinus occlusion in a boy presenting with asparaginase-induced hypertriglyceridemia.
Hypertriglyceridemia
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.
Hypertriglyceridemia
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Hypertriglyceridemia
Lipid Apheresis to Manage Severe Hypertriglyceridemia during Induction Therapy in a Child with Acute Lymphoblastic Leukemia.
Hypertriglyceridemia
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Hypertriglyceridemia
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Hypertriglyceridemia
Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.
Hypertriglyceridemia
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Hypertriglyceridemia
Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.
Hypertriglyceridemia
Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.
Hypertriglyceridemia
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Hypertriglyceridemia
[Severe hypertriglyceridemia secondary to asparaginase administered to adult patients: report of 2 cases and literature review].
Hypoalbuminemia
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Hypoglycemia
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Hyponatremia
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Hypotension
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Infections
Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.
Infections
Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service.
Infections
Asparagine deprivation mediated by Salmonella asparaginase causes suppression of activation-induced T cell metabolic reprogramming.
Infections
Identification and validation of l-asparaginase as a potential metabolic target against Mycobacterium tuberculosis.
Infections
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Insulin Resistance
Association between body mass index and insulin resistance in survivors of pediatric acute lymphoblastic leukemia.
Insulin Resistance
Body mass index predicts insulin resistance in survivors of pediatric acute lymphoblastic leukemia.
Invasive Fungal Infections
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Lentivirus Infections
RNAi?mediated downregulation of asparaginase?like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.
Leukemia
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Leukemia
A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia.
Leukemia
A sulfoximine-based inhibitor of human asparagine synthetase kills l-asparaginase-resistant leukemia cells.
Leukemia
Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Leukemia
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.
Leukemia
Analysis of long-term survival in acute leukemia and Burkitt's tumor--effects to be expected from intensive therapy and asparaginase.
Leukemia
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Leukemia
Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis.
Leukemia
Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Leukemia
Asparaginase immune complexes induce Fc-?RIII-dependent hypersensitivity in naive mice.
Leukemia
Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.
Leukemia
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Leukemia
Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy Against Brain Tumors.
Leukemia
Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling.
Leukemia
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.
Leukemia
Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany.
Leukemia
Cerebral Venous Sinus Thrombosis in Pediatric Cancer Patients: Long-term Neurological Outcomes.
Leukemia
Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Leukemia
Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Leukemia
Cholelithiasis and choledocholithiasis after sequential cytarabine and asparaginase.
Leukemia
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
Leukemia
Cloning, expression, purification and characterisation of Erwinia carotovora L-asparaginase in Escherichia coli.
Leukemia
Comparison of crystalline and amorphous asparaginase in treatment of acute leukemia in children.
Leukemia
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Leukemia
Critical influence of an enzyme-elevating virus upon long-term remissions of mouse leukemia following asparaginase therapy.
Leukemia
Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia.
Leukemia
Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation.
Leukemia
Differentiation versus cytoreduction during remission induction in acute nonlymphoblastic leukemia treated with sequential high-dose ara-C and asparaginase.
Leukemia
Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia.
Leukemia
Dose-related pharmacologic effects of high dose ara-C and its use in combination with asparaginase for the treatment of patients with acute non-lymphocytic leukemia.
Leukemia
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Leukemia
Exceptional thermal stability of therapeutical enzymes entrapped in alumina sol-gel matrices.
Leukemia
Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.
Leukemia
Free Asparagine or Die: Cancer Cells Require Proteasomal Protein Breakdown to Survive Asparagine Depletion.
Leukemia
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
Leukemia
Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia.
Leukemia
Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Leukemia
High-dose Ara-C (HiDAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian Cooperative Group GIMEMA.
Leukemia
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Leukemia
Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors Fc?RI and Fc?RIII.
Leukemia
Idiopathic Hyperammonemia That Developed During Initial Treatment With Steroid in a Patient With Newly Diagnosed Leukemia.
Leukemia
IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Leukemia
Improvement of stability and enzymatic activity by site-directed mutagenesis of E. coli asparaginase II.
Leukemia
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Leukemia
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Leukemia
L-asparaginase production review: bioprocess design and biochemical characteristics.
Leukemia
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
Leukemia
Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Leukemia
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Leukemia
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Leukemia
Preliminary results of the combination methotrexate-asparaginase in patients with acute non lymphoid leukemia.
Leukemia
Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Leukemia
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Leukemia
Proteins from Erwinia asparaginase Erwinase(®) and E. coli asparaginase 2 MEDAC(®) for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Leukemia
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Leukemia
Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells.
Leukemia
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report.
Leukemia
Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
Leukemia
Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.
Leukemia
Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma.
Leukemia
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma.
Leukemia
Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
Leukemia
Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias.
Leukemia
Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia.
Leukemia
Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia.
Leukemia
Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan.
Leukemia
Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Leukemia
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Leukemia
Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias.
Leukemia
Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia.
Leukemia
Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
Leukemia
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Leukemia
Use of asparaginase in conjunction with cytosine arabinoside in acute leukemia in children.
Leukemia
[A technic for "desensitization" in case of asparaginase anaphylaxis during acute leukemia]
Leukemia
[Results of the treatment of acute leukemias in children with asparaginase (critical study of 34 cases)]
Leukemia
[Sequential high-dose cytarabine therapy in combination with asparaginase in acute myeloid leukemia]
Leukemia
[The use of asparaginase preparations for the treatment of tumors and leukemia (review of the literature)]
Leukemia P388
Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part III--Combination experiments.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment of Pegylated Asparaginase-Induced Hypertriglyceridemia with Continuous Intravenous Infusion of Insulin and Heparin: A Case Report.
Leukemia, Myeloid
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Leukemia, Myeloid
Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells.
Leukemia, Myeloid, Acute
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Leukemia, Myeloid, Acute
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany.
Leukemia, Myeloid, Acute
Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Leukemia, Myeloid, Acute
Differentiation versus cytoreduction during remission induction in acute nonlymphoblastic leukemia treated with sequential high-dose ara-C and asparaginase.
Leukemia, Myeloid, Acute
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Leukemia, Myeloid, Acute
Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.
Leukemia, Myeloid, Acute
L-asparaginase production review: bioprocess design and biochemical characteristics.
Leukemia, Myeloid, Acute
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Leukemia, Myeloid, Acute
Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.
Leukemia, Myeloid, Acute
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Leukemia, Myeloid, Acute
The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Leukemia, Myeloid, Acute
[Sequential high-dose cytarabine therapy in combination with asparaginase in acute myeloid leukemia]
Leukemia, Promyelocytic, Acute
Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Leukemia, T-Cell
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Leukopenia
Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma--a rationale for tailored supportive care.
Leukopenia
Profound leukopenia following asparaginase treatment in a patient with acute lymphoblastic leukaemia.
Liver Diseases
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Liver Diseases
GCN2 is required to increase fibroblast growth factor 21 and maintain hepatic triglyceride homeostasis during asparaginase treatment.
Liver Diseases
Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
Liver Diseases
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Liver Failure
Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.
Liver Failure
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Liver Failure, Acute
Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
Liver Failure, Acute
Natural Killer-Like T-Cell Lymphoma: A Rare Cause of Acute Liver Failure.
Liver Neoplasms
On the liver asparaginase in the course of liver cancer production of rats fed on azo dye.
Lymphatic Metastasis
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
Lymphoma
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Lymphoma
A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
Lymphoma
An urchin-like helical polypeptide-asparaginase conjugate with mitigated immunogenicity.
Lymphoma
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Lymphoma
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Lymphoma
Asparagine synthetase expression is associated with the sensitivity to asparaginase in extranodal natural killer/T-cell lymphoma in vivo and in vitro.
Lymphoma
Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.
Lymphoma
Chemical modification of L-asparaginase with comb-shaped copolymer of poly(ethylene glycol) derivative and maleic anhydride.
Lymphoma
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Lymphoma
Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
Lymphoma
Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).
Lymphoma
Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Lymphoma
Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Lymphoma
Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Lymphoma
E. coli-Derived L-Asparaginase Retains Enzymatic and Cytotoxic Activity In Vitro for Canine and Feline Lymphoma after Cold Storage.
Lymphoma
Effect of asparaginase on cell membranes of sensitive and resistant mouse lymphoma cells.
Lymphoma
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Lymphoma
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Lymphoma
Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells.
Lymphoma
Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Lymphoma
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Lymphoma
LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.
Lymphoma
LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.
Lymphoma
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Lymphoma
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.
Lymphoma
Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.
Lymphoma
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Lymphoma
Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
Lymphoma
Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Lymphoma
Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Lymphoma
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Lymphoma
Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma.
Lymphoma
Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma.
Lymphoma
Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy.
Lymphoma
Ultrasound-propelled nanowire motors enhance asparaginase enzymatic activity against cancer cells.
Lymphoma
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
Lymphoma
[Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
Lymphoma
[Isolation and properties of a homogeneous L-asparaginase preparation from Pseudomonas fluorescens AG]
Lymphoma
[Preparation of repeatedly and effectively usable L-asparaginase by a chemical modification]
Lymphoma, B-Cell
[Effect of Asparaginase on Diffuse Large B-Cell Lymphoma Cell Apoptosis and Its Related Mechanism].
Lymphoma, Large B-Cell, Diffuse
Biochemical and pathophysiological characterization of Helicobacter pylori asparaginase.
Lymphoma, Large B-Cell, Diffuse
[Effect of Asparaginase on Diffuse Large B-Cell Lymphoma Cell Apoptosis and Its Related Mechanism].
Lymphoma, Mantle-Cell
A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Lymphoma, Non-Hodgkin
Amino acids of the 6C3HED lymphosarcoma following treatment with asparaginase.
Lymphoma, Non-Hodgkin
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Lymphoma, Non-Hodgkin
Cerebral Venous Sinus Thrombosis in Pediatric Cancer Patients: Long-term Neurological Outcomes.
Lymphoma, Non-Hodgkin
Changes in ribonuclease activities in P1798 lymphosarcoma after asparaginase treatment.
Lymphoma, Non-Hodgkin
Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
Lymphoma, Non-Hodgkin
Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
Lymphoma, Non-Hodgkin
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Lymphoma, Non-Hodgkin
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Lymphoma, Non-Hodgkin
Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Lymphoma, Non-Hodgkin
Saccharomyces cerevisiae asparaginase II, a potential antileukemic drug: Purification and characterization of the enzyme expressed in Pichia pastoris.
Lymphoma, Non-Hodgkin
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
Lymphoma, Non-Hodgkin
The properties and large-scale production of L-asparaginase from citrobacter.
Lymphoma, Non-Hodgkin
TRANSIENT HYPERAMMONEMIA DUE TO L -ASPARAGINASE THERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR NON-HODGKIN LYMPHOMA.
Lymphoma, Non-Hodgkin
[Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin's lymphoma. Report of the Polish Paediatric LeuKaemia/Lymphoma Study Group]
Lymphoma, T-Cell
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Lymphoproliferative Disorders
Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.
Medulloblastoma
Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma.
Meningitis
[Allergic meningitis due to asparaginase sensitivity during acute lymphoblastic leukemia]
Meningitis
[Leukemic meningitis, purulent meningitis, allergic meningitis due to asparaginase sensitization: successive episodes in the course of acute lymphoblastic leukemia]
Mesenteric Ischemia
Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase.
Mouth Neoplasms
Asparaginase induces selective dose- and time-dependent cytotoxicity, apoptosis, and reduction of NF?B expression in oral cancer cells.
Myelodysplastic Syndromes
Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany.
Neoplasm Metastasis
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
Neoplasm Metastasis
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Neoplasm, Residual
High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
Neoplasm, Residual
Inherited GATA3 variant associated with positive minimal residual disease in childhood B-cell acute lymphoblastic leukemia via asparaginase resistance.
Neoplasm, Residual
Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Neoplasm, Residual
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]
Neoplasms
A newly identified glutaminase-free ?-asparaginase (?-ASPG86) from a marine bacterium Mesoflavibacter zeaxanthinifaciens.
Neoplasms
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Neoplasms
Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model.
Neoplasms
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Neoplasms
Antithrombin III during high-dose cytosine arabinoside therapy with or without asparaginase.
Neoplasms
Antitumor activity and ability to prevent acrylamide formation in fried foods of asparaginase from soybean root nodules.
Neoplasms
As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid.
Neoplasms
Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Neoplasms
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Neoplasms
Asparaginase induces selective dose- and time-dependent cytotoxicity, apoptosis, and reduction of NF?B expression in oral cancer cells.
Neoplasms
Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Neoplasms
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Neoplasms
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Neoplasms
Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase.
Neoplasms
Asparagine Synthetase: Regulation by Cell Stress and Involvement in Tumor Biology.
Neoplasms
Bacillus sonorensis L. Asparaginase: Cloning, Expression in E. coli and Characterization.
Neoplasms
BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
Neoplasms
Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2.
Neoplasms
Carbon nanoparticle from a natural source fabricated for folate receptor targeting, imaging and drug delivery application in A549 lung cancer cells.
Neoplasms
Characterisation and molecular dynamic simulations of J15 asparaginase from Photobacterium sp. strain J15.
Neoplasms
Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.
Neoplasms
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Neoplasms
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Neoplasms
Crystal structure of active site mutant of antileukemic l-asparaginase reveals conserved zinc-binding site.
Neoplasms
Deprivation of asparagine triggers cytoprotective autophagy in laryngeal squamous cell carcinoma.
Neoplasms
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents.
Neoplasms
Discovery of why acute lymphoblastic leukaemia cells are killed by asparaginase: Adventures of a young post-doctoral student, Bertha K Madras.
Neoplasms
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Neoplasms
Effects of A6E Mutation on Protein Expression and Supramolecular Assembly of Yeast Asparagine Synthetase.
Neoplasms
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Neoplasms
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101].
Neoplasms
Free Asparagine or Die: Cancer Cells Require Proteasomal Protein Breakdown to Survive Asparagine Depletion.
Neoplasms
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.
Neoplasms
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
Neoplasms
How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
Neoplasms
Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Neoplasms
Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes.
Neoplasms
Immunological effects of native and polyethylene glycol-modified asparaginases from Vibrio succinogenes and Escherichia coli in normal and tumour-bearing mice.
Neoplasms
Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group.
Neoplasms
Improvement of stability and enzymatic activity by site-directed mutagenesis of E. coli asparaginase II.
Neoplasms
In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria.
Neoplasms
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Neoplasms
Increased expression of ASRGL1 in invasive ductal carcinoma and its association with estrogen-progesterone receptor status of tumors.
Neoplasms
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.
Neoplasms
Insights into the microbial L-asparaginases: from production to practical applications.
Neoplasms
Isolation, purification, characterisation and application of L-ASNase (L-ASNase): A review.
Neoplasms
L-asparaginase production review: bioprocess design and biochemical characteristics.
Neoplasms
L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
Neoplasms
l-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
Neoplasms
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Neoplasms
Molecular Cloning, Biochemical Characterization, and Antitumor Properties of a Novel L-Asparaginase from Synechococcus elongatus PCC6803.
Neoplasms
Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
Neoplasms
Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent Wnt Activation in Colorectal Cancer.
Neoplasms
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Neoplasms
Production and structural modeling of a novel asparaginase in Yarrowia lipolytica.
Neoplasms
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Neoplasms
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Neoplasms
Purification and Characterization of Glutaminase Free Asparaginase from Enterobacter cloacae: In-Vitro Evaluation of Cytotoxic Potential against Human Myeloid Leukemia HL-60 Cells.
Neoplasms
Purification and Some Biological Properties of Asparaginase from Azotobacter vinelandii.
Neoplasms
Recent developments in l-asparaginase discovery and its potential as anticancer agent.
Neoplasms
Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome.
Neoplasms
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Neoplasms
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Neoplasms
RNAi?mediated downregulation of asparaginase?like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.
Neoplasms
Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
Neoplasms
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Neoplasms
The effect on macromolecular synthesis of amino acid deprivation of hamster kidney cells.
Neoplasms
The preparation of insoluble, matrix-supported derivatives of asparaginase for use in cancer therapy.
Neoplasms
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Neoplasms
Therapy of acute lymphoblastic leukaemia in childhood: effects on the nervous system.
Neoplasms
Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study.
Neoplasms
Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Neoplasms
Tumour regression with liposome-entrapped asparaginase: some immunological advantages.
Neoplasms
Two tagging single-nucleotide polymorphisms to capture HLA-DRB1*07:01-DQA1*02:01-DQB1*02:02 haplotype associated with asparaginase hypersensitivity.
Neoplasms
Ultrasound-propelled nanowire motors enhance asparaginase enzymatic activity against cancer cells.
Neoplasms
Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.
Neoplasms
[Activity of asparaginase and glutaminase of chickens with experimental sarcomatosis]
Neoplasms
[Antitumor activity of L-asparaginase from Erwinia carotovora from against different leukemic and solid tumours cell lines].
Neoplasms
[Monoaminodicarboxylic acids and their amides in tissues during regressive tumor growth]
Neoplasms
[Physico-chemical properties of deamidase AG from Pseudomonas fluorescens AG possessing antitumor activity]
Neoplasms
[Severe acute pancreatitis in children receiving asparaginase: multicenter retrospective study]
Neoplasms
[Study of glutaminase and asparaginase activities in normal tissues and malignant tumors]
Neoplasms
[The enzyme asparaginase as a possible cytostaticum in therapy of malignant tumor in the jaw face region]
Neoplasms
[The use of asparaginase preparations for the treatment of tumors and leukemia (review of the literature)]
Neoplastic Processes
Antibody-producing cells: virus-induced alteration of response to antigen.
Neuritis
Asparaginase in peripheral nerves of the guinea pig in Wallerian degeneration and experimental allergic neuritis.
Neuritis, Autoimmune, Experimental
Asparaginase in peripheral nerves of the guinea pig in Wallerian degeneration and experimental allergic neuritis.
Obesity
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Obesity
Management of osteonecrosis in children and young adults with acute lymphoblastic leukaemia.
Obesity
Obesity Challenges the Hepatoprotective Function of the Integrated Stress Response to Asparaginase Exposure in Mice.
Obesity
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Osteonecrosis
A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday.
Osteonecrosis
Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.
Osteonecrosis
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model.
Osteonecrosis
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Osteonecrosis
Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia.
Osteonecrosis
Osteonecrosis in Adults With Acute Lymphoblastic Leukemia: An Unmet Clinical Need.
Osteonecrosis
Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia.
Overweight
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Pancreatic Neoplasms
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101].
Pancreatic Neoplasms
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Pancreatic Pseudocyst
Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase.
Pancreatitis
Acute Pancreatitis Associated With Cytarabine During the Treatment of Pediatric Acute Myeloid Leukemia.
Pancreatitis
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Pancreatitis
Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Pancreatitis
Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study.
Pancreatitis
Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia.
Pancreatitis
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.
Pancreatitis
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Pancreatitis
Asparagine Synthetase Is Highly Expressed at Baseline in the Pancreas Through Heightened PERK Signaling.
Pancreatitis
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.
Pancreatitis
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
Pancreatitis
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Pancreatitis
Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia.
Pancreatitis
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Pancreatitis
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Pancreatitis
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Pancreatitis
General control nonderepressible kinase 2 (GCN2) deletion predisposes to asparaginase-associated pancreatitis in mice.
Pancreatitis
Genetic markers for treatment-related pancreatitis in a cohort of Hispanic children with acute lymphoblastic leukemia.
Pancreatitis
Iatrogenic pancreatitis. A fatal complication in the induction therapy for acute lymphocytic leukemia.
Pancreatitis
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Pancreatitis
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Pancreatitis
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.
Pancreatitis
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia.
Pancreatitis
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Pancreatitis
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Pancreatitis
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Pancreatitis
Pancreatitis in a child with acute lymphoblastic leukemia after Erwinia asparaginase: Evaluation of ultrasonography and computerized tomography as diagnostic tools.
Pancreatitis
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Pancreatitis
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Pancreatitis
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Pancreatitis
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Pancreatitis
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Pancreatitis
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Pancreatitis
Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.
Pancreatitis
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Pancreatitis
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Pancreatitis
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Pancreatitis
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
Pancreatitis
[Severe acute pancreatitis in children receiving asparaginase: multicenter retrospective study]
Pancreatitis, Acute Hemorrhagic
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Pancreatitis, Acute Hemorrhagic
[Acute hemorrhagic pancreatitis caused by asparaginase. A case in a child with a favorable course]
Pancreatitis, Acute Hemorrhagic
[Acute severe steatosis following an acute necrotic, hemorrhagic pancreatitis after treatment with asparaginase]
Pancreatitis, Acute Necrotizing
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
Parasitemia
Knockdown of asparagine synthetase A renders Trypanosoma brucei auxotrophic to asparagine.
Peripheral Nervous System Diseases
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Peripheral Nervous System Diseases
Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia.
Peripheral Nervous System Diseases
Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.
Phenylketonurias
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Posterior Leukoencephalopathy Syndrome
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adequate asparaginase is important to prevent central nervous system and testicular relapse of pediatric Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adult acute lymphoblastic leukemia: results of the Iowa HOP-L protocol.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Albumin/asparaginase capsules prepared by ultrasound to retain ammonia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allergic reactions to asparaginase: Retrospective cohort study in pediatric patients with acute lymphoid leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Allergic-like reactions to asparaginase: Atypical allergies without asparaginase inactivation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ammonia levels should not be used as a surrogate marker of levels of asparaginase activity in acute lymphoblastic leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Application of repeated aspartate tags to improving extracellular production of Escherichia coli L-asparaginase isozyme II.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase in combination chemotherapy for remission induction of childhood acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase inhibits the lectin pathway of complement activation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase products in upfront acute lymphoblastic leukemia therapy: Value, location, and style.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase use for the treatment of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with PEG-Asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparagine synthetase: Function, structure, and role in disease.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Asparagine Synthetase: Regulation by Cell Stress and Involvement in Tumor Biology.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cerebral Sinus Venous Thrombosis due to Asparaginase Therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Characterization of a recombinant glutaminase-free L-asparaginase (ansA3) enzyme with high catalytic activity from Bacillus licheniformis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical application of asparaginase activity levels following treatment with pegaspargase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cloning, expression and characterization of L-asparaginase from Pseudomonas fluorescens for large scale production in E. coli BL21.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cloning, expression and characterization of l-asparaginase from Withania somnifera L. for large scale production.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Complete blood count using VCS (volume, conductivity, light scatter) technology is affected by hyperlipidemia in a child with acute leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Construction of expression systems for Escherichia coli asparaginase II and two-step purification of the recombinant enzyme from periplasmic extracts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Crystal structure of active site mutant of antileukemic l-asparaginase reveals conserved zinc-binding site.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Diabetic ketoacidosis following PEG-asparaginase therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dose Intensification of Methotrexate and Cytarabine During Intensified Continuation Chemotherapy for High-risk B-Precursor Acute Lymphoblastic Leukemia: POG 9406: A Report From the Children's Oncology Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Dural sinus thrombosis in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effects of A6E Mutation on Protein Expression and Supramolecular Assembly of Yeast Asparagine Synthetase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Engineering Cell-Free Protein Synthesis for High-Yield Production and Human Serum Activity Assessment of Asparaginase: Toward On-Demand Treatment of Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enhanced catalysis of l-asparaginase from Bacillus licheniformis by a rational redesign.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Erroneous Exchange of Asparaginase Forms in the Treatment of Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Establishment and characterization of a novel childhood acute lymphoblastic leukemia cell line, HXEX-ALL1, with chromosome 9p and 17p deletions.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Establishment of asparaginase- and guinea pig complement-resistant subline of murine lymphoblastic leukemia L5178y cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Evaluation of Antineoplastic Activity of Extracellular Asparaginase Produced by Isolated Bacillus circulans.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Excessive toxicities of pegylated asparaginase in pediatric acute lymphoblastic leukemia patients with high body surface area: A call for action.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression and characterization of recombinant l-asparaginase from Pseudomonas fluorescens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Five-year single-center study of asparaginase therapy within the ALL-BFM 2000 trial.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glucose Levels Before the Onset of Asparaginase Predicts Transient Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
High-throughput asparaginase activity assay in serum of children with leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hyperammonemia secondary to asparaginase: A case series.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Iatrogenic pancreatitis. A fatal complication in the induction therapy for acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Improved treatment results of non-Hodgkin's lymphoma in children: a report from the Children's Cancer and Leukemia Study Group of Japan.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Improving the Treatment of Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inherited GATA3 variant associated with positive minimal residual disease in childhood B-cell acute lymphoblastic leukemia via asparaginase resistance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Insulin infusion to treat severe hypertriglyceridemia associated with pegaspargase therapy: a case report.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interaction between Gallic acid and Asparaginase to potentiate anti-proliferative effect on lymphoblastic leukemia cell line.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interaction of alpha 2-macroglobulin with L-asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IV Administration of Erwinia-Derived Asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia: Single-Centre Case Series.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-asparaginase production review: bioprocess design and biochemical characteristics.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-Asparaginase-Induced Hepatotoxicity Treated Successfully With L-Carnitine and Vitamin B Infusion.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lipid Apheresis to Manage Severe Hypertriglyceridemia during Induction Therapy in a Child with Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Liposomal Daunorubicin (Daunoxome) and Polyethylated Glycol Conjugated Asparaginase (PEG-ASPA) in Children with Relapsed and Refractory Acute Lymphoblastic Leukemia Treated on Compassionate Basis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Low-dosage asparaginase treatment of childhood acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Low-molecular-weight heparin in pediatric patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Microbial production, molecular modification, and practical application of l-Asparaginase: A review.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Microchip CE-LIF method for the hydrolysis of L-glutamine by using L-asparaginase enzyme reactor based on gold nanoparticle.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Micronucleus incidence and their chromosomal origin related to therapy in acute lymphoblastic leukemia (ALL) patients: detection by micronucleus and FISH techniques.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Molecular cloning, structural modeling and production of recombinant Aspergillus terreusl. asparaginase in Escherichia coli.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Negligible hemostatic toxicity of intermediate-dose Erwinase in adult patients with acute lymphoblastic leukemia: preliminary data.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Optimization of culture conditions and bench-scale production of anticancer enzyme L-asparaginase by submerged fermentation from Aspergillus terreus CCT 7693.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pain intensity and bioavailability of intramuscular asparaginase and a local anesthetic: a double-blinded study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pancreatitis in a child with acute lymphoblastic leukemia after Erwinia asparaginase: Evaluation of ultrasonography and computerized tomography as diagnostic tools.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Peg-asparaginase for acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PEG-asparaginase induced severe hypertriglyceridemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia ().
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pegylated asparaginase in front-line treatment of children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children's plasma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Plasmapheresis in asparaginase-induced hypertriglyceridemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Population pharmacokinetics of native Escherichia coli asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prevalence of transient hyperglycemia during induction chemotherapy for pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Production of a novel N-terminal PEGylated crisantaspase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Proteins from Erwinia asparaginase Erwinase(®) and E. coli asparaginase 2 MEDAC(®) for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Purification and characterization of glutaminase free asparaginase from Pseudomonas otitidis: Induce apoptosis in human leukemia MOLT-4 cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reactions related to asparaginase infusion in a 10-year retrospective cohort.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reinduction therapy for advanced or refractory acute lymphoblastic leukemia of childhood.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reinforced HEAV'D therapy for adult acute lymphoblastic leukemia: improved results and revised prognostic criteria.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Reply to comment on: Glucose levels before the onset of asparaginase predicts transient hyperglycemia in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Rhizobium etli asparaginase II: An alternative for acute lymphoblastic leukemia (ALL) treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Safety and Efficacy of Metformin for Therapy-induced Hyperglycemia in Children With Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children with Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Space for Calaspargase? A New Asparaginase for Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful management of extreme hypertriglyceridemia in a child with acute lymphoblastic leukemia by temporarily omitting dexamethasone while continuing asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tackling Critical Catalytic Residues in Helicobacter pylori L-Asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting the Proline-Glutamine-Asparagine-Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The eukaryotic initiation factor 2 (eIF2) kinase GCN2 protects against hepatotoxicity during asparaginase treatment.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The impact of prophylactic fresh frozen plasma and cryoprecipitate on the incidence of CNS thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The long-term impact of in vitro drug sensitivity testing on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutic drug monitoring of asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-asparaginase in the AIEOP-BFM ALL 2009 study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Thyroid function is not affected by second exposure to erwinia asparaginase for childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TRANSIENT HYPERAMMONEMIA DUE TO L -ASPARAGINASE THERAPY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR NON-HODGKIN LYMPHOMA.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Treatment of severe hypertriglyceridemia associated with accidental pegylated asparaginase push in a child with relapsed acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Acute necrotic pancreatitis secondary to asparaginase. Role of drug combinations--early diagnosis and treatment. Apropos of 2 cases]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Allergic meningitis due to asparaginase sensitivity during acute lymphoblastic leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[COALL-80 therapy in the management of acute lymphoblastic leukemia in childhood--an interim report]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Effect of E coli or Erwinia asparaginase and corticotherapy on fibrinogen concentration in induction of acute lymphoblastic leukemia in children]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Fatal central nervous system hemorrhage during acute lymphoblastic leukemia induction].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Hypersensitivity reactions associated with the use of asparaginase in children with acute lymphoblastic leukemia].
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[L-asparaginase study results (phase II of the clinical trials)]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Leukemic meningitis, purulent meningitis, allergic meningitis due to asparaginase sensitization: successive episodes in the course of acute lymphoblastic leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Treatment of acute lymphoid leukemia in adults]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
[Venous thrombosis of cranial sinuses in asparaginase therapy. A case report]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Recent Advances in the Management of Acute Lymphoblastic Leukaemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Results of successive EORTC-CLG 58 881 and 58 951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL).
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Prostatic Neoplasms
Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.
Pulmonary Disease, Chronic Obstructive
Screening of immunosuppressive cells from colorectal adenocarcinoma and identification of prognostic markers.
Pulmonary Embolism
Haemostatic alterations induced by treatment with asparaginases and clinical consequences.
Respiratory Insufficiency
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Retinal Degeneration
A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration.
Retinal Dystrophies
A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration.
Sarcoma
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma.
Sarcoma
[Monoaminodicarboxylic acids and their amides in tissues during regressive tumor growth]
Seizures
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Sepsis
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Sinus Thrombosis, Intracranial
Dural sinus thrombosis in children with acute lymphoblastic leukemia.
Sinus Thrombosis, Intracranial
Inherited thrombophilic factors do not increase central venous catheter blockage in children with malignancy.
Starvation
Asparagine metabolism and nitrogen distribution during protein degradation in sugar-starved maize root tips.
Starvation
Insights into the microbial L-asparaginases: from production to practical applications.
Starvation
L-asparaginase II of saccharomyces cerevisiae. Activity profile during growth using an ure2 mutant P40-3C and a P40-3C + URE2p strain.
Starvation
The effect on macromolecular synthesis of amino acid deprivation of hamster kidney cells.
Starvation
The eIF2 kinase GCN2 is essential for the murine immune system to adapt to amino acid deprivation by asparaginase.
Starvation
Transport and metabolic effects of alpha-aminoisobutyric acid in Saccharomyces cerevisiae.
Starvation
[Asparaginase and adenosine deaminase activity in the liver tissue of rats parenterally administered nitrogenous preparations in protein starvation]
Stomach Neoplasms
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Stomach Ulcer
Role of ?-glutamyl transpeptidase in the pathogenesis of Helicobacter pylori infection.
Superior Vena Cava Syndrome
Anaphylaxis and superior vena cava thrombus in a pediatric patient with acute lymphoblastic leukemia.
Tetanus
Asparaginase Display of Human Cholesteryl Ester Transfer Protein (CETP) B Cell Epitopes for Inducing High Titers of Anti-CETP Antibodies In Vivo.
Thrombocytopenia
Thromboembolic complications related to indwelling central venous catheters in children.
Thrombocytosis
Asparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis.
Thromboembolism
Central venous line-related thromboembolism is common in children with non-high risk acute lymphoblastic leukaemia.
Thromboembolism
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Thromboembolism
Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Thromboembolism
The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia.
Thromboembolism
Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Thromboembolism
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years.
Thromboembolism
Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
Thrombophilia
Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer--a prospective study.
Thrombosis
A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia.
Thrombosis
An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Thrombosis
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Thrombosis
Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia?.
Thrombosis
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
Thrombosis
Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
Thrombosis
Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.
Thrombosis
Clinical importance of prothrombotic risk factors in pediatric patients with malignancy--impact of central venous lines.
Thrombosis
Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase.
Thrombosis
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Thrombosis
Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Thrombosis
Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Thrombosis
Incidence and risk factors for Central Nervous System thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre cohort study.
Thrombosis
Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Thrombosis
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion.
Thrombosis
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion.
Thrombosis
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.
Thrombosis
Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase.
Thrombosis
Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Thrombosis
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Thrombosis
The impact of prophylactic fresh frozen plasma and cryoprecipitate on the incidence of CNS thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase.
Thrombosis
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH.
Thrombosis
The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia.
Thrombosis
The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
Thrombosis
Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients.
Thrombosis
Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Thrombosis
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.
Thrombosis
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]
Thrombosis
[Thrombosis in children with acute lymphoblastic leukemia treated with the COALL protocol]
Toxemia
Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.
Triple Negative Breast Neoplasms
Pseudomonas aeruginosa recombinant L-asparaginase: Large scale production, purification, and cytotoxicity on THP-1, MDA-MB-231, A549, Caco2 and HCT-116 cell lines.
Tuberculosis
Mycobacterium tuberculosis exploits asparagine to assimilate nitrogen and resist acid stress during infection.
Tuberous Sclerosis
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Urea Cycle Disorders, Inborn
Pegylated asparaginase as cause of fatal hyperammonemia in patients with latent urea cycle disorder.
Urticaria
Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
Uterine Cervical Neoplasms
RNAi?mediated downregulation of asparaginase?like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa.
Venous Thromboembolism
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Venous Thromboembolism
Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Venous Thromboembolism
Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Venous Thrombosis
A minor role of asparaginase in predisposing to cerebral venous thromboses in adult acute lymphoblastic leukemia patients.
Venous Thrombosis
Age at cancer diagnosis, non-O blood group and asparaginase therapy are independently associated with deep venous thrombosis in pediatric oncology patients: A risk model.
Venous Thrombosis
Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Venous Thrombosis
Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
Venous Thrombosis
Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase.
Venous Thrombosis
Haemostatic alterations induced by treatment with asparaginases and clinical consequences.
Venous Thrombosis
Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
Venous Thrombosis
Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management.
Venous Thrombosis
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH.
Venous Thrombosis
Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.
Venous Thrombosis
[Venous thrombosis of cranial sinuses in asparaginase therapy. A case report]
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). ASGL1_HUMAN
308
0
32055
Swiss-Prot
other Location (Reliability: 3)
LPP60_HUMAN
573
0
60883
Swiss-Prot
Mitochondrion (Reliability: 5)
G3V1Y8_HUMAN
555
0
59883
TrEMBL
Mitochondrion (Reliability: 5)
B3KR33_HUMAN
308
0
32097
TrEMBL
other Location (Reliability: 3)
Q9BRH2_HUMAN
199
0
20969
TrEMBL
other Location (Reliability: 2)
A0A024R573_HUMAN
308
0
32055
TrEMBL
other Location (Reliability: 3)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
hanging drop vapor diffusion method, using 2.2-2.5 M sodium malonate (pH 7.0)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
RENATURED/Commentary
ORGANISM
UNIPROT
LITERATURE
the refolding efficiency of recombinant enzyme from inclusion bodies is maximal at pH 8.5 (84%) and temperature 25°C (86%)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
diagnostics
-
the enzyme is a marker of chemotherapy dose modification during the induction phase in children with acute lymphoblastic leukemia, overview
medicine
-
the enzyme is widely used in chemotherapy for treatment of children with acute lymphoblastic leukemia, in vivo and in vitro resistance of the cells to the enzyme can occur
synthesis
optimization of production and process conditions for recombinant human enzyme. The maximum biomass yield of 6.7 g/l of enzyme is achieved with fed-batch fermentation. The refolding efficiency is optimal at pH 8.5 (84%) and temperature 25°C (86%)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Stams, W.A.; den Boer, M.L.; Holleman, A.; Appel, I.M.; Beverloo, H.B.; van Wering, E.R.; Janka-Schaub, G.E.; Evans, W.E.; Pieters, R.
Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia
Blood
105
4223-4225
2005
Homo sapiens
brenda
Baillargeon, J.; Langevin, A.; Lewis, M.; Thomas, P.J.; Mullins, J.; Dugan, J.; Pollock, B.H.
L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia
Cancer
104
2858-2861
2005
Homo sapiens
brenda
Nomme, J.; Su, Y.; Lavie, A.
Elucidation of the specific function of the conserved threonine triad responsible for human L-asparaginase autocleavage and substrate hydrolysis
J. Mol. Biol.
426
2471-2485
2014
Homo sapiens (Q7L266), Homo sapiens
brenda
Kante, R.K.; Vemula, S.; Somavarapu, S.; Mallu, M.R.; Boje Gowd, B.H.; Ronda, S.R.
Optimized upstream and downstream process conditions for the improved production of recombinant human asparaginase (rhASP) from Escherichia coli and its characterization
Biologicals
56
45-53
2018
Homo sapiens (Q7L266), Homo sapiens
brenda
EXTERNAL LINKS (specific for EC-Number 3.5.1.1)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
